Athira Pharma Highlights Presentation Of Alzheimer's Data
Portfolio Pulse from Benzinga Newsdesk
Athira Pharma has presented new preclinical data at the Alzheimer's Association International Conference in Amsterdam, demonstrating the neuroprotective effects of fosgonimeton in models of amyloid-ß-mediated toxicity. Additionally, ATH-1105 has shown protection against pathologies common to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
July 17, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Athira Pharma's new preclinical data on fosgonimeton and ATH-1105 could potentially boost investor confidence in the company's research and development capabilities.
The presentation of promising preclinical data at a major international conference is a positive development for Athira Pharma. This could potentially lead to increased investor confidence in the company's research and development capabilities, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100